ASND logo

Ascendis Pharma A/S (ASND) Cash From Financing

Annual CFF

$480.49 M
+$335.10 M+230.49%

December 31, 2024

Summary

Performance

1-Year Change

+230.49%

3-Year Change

+15.57%

5-Year Change

-13.05%

15-Year Change

+240.17%

ASND Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

96.62%
ASND annual cash flow from financing activities is higher than 96.62% of companies in Healthcare sector

High & Low

All-time High

$688.24 M
ASND annual cash flow from financing activities is currently -30.19% below its historical high of $688.24 million

3-Year Low

$145.39 M
ASND annual cash flow from financing activities is currently +230.49% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2024
ASND previous annual earnings announcement was published on Dec 31, 2024

Next Annual Earnings Report Date

N/A
ASND next annual earnings announcement has not yet been scheduled

OtherASNDcash flowmetrics:

Annual CFI

$7.44 M
ASND annual cash flow from investing activities is $7.44 million

Annual CFO

-$331.41 M
ASND annual cash flow from operations is -$331.41 million

Annual FCF

-$332.96 M
ASND annual free cash flow is -$332.96 million

Annual CAPEX

$1.54 M
ASND annual capital expenditures is $1.54 million

Quarterly CFF

N/A

December 31, 2024

Summary

Performance

3-Month Change

-

1-Year Change

-

3-Year Change

-

5-Year Change

-

ASND Quarterly CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$684.23 M
ASND quarterly cash flow from financing activities is currently at an all-time high

3-Year Low

-$25.03 M
ASND quarterly cash flow from financing activities is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
ASND previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 2, 2025
ASND next earnings announcement is scheduled for May 2, 2025

OtherASNDcash flowmetrics:

Quarterly CFI

-
ASND quarterly cash flow from investing activities value is unknown

Quarterly CFO

-
ASND quarterly cash flow from operations value is unknown

Quarterly FCF

-
ASND quarterly free cash flow value is unknown

Quarterly CAPEX

-
ASND quarterly capital expenditures value is unknown

TTM CFF

N/A

December 31, 2024

Summary

Performance

3-Month Change

-

1-Year Change

-

3-Year Change

-

5-Year Change

-

ASND TTM CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$862.04 M
ASND TTM cash flow from financing activities is currently at an all-time high

3-Year Low

-$28.62 M
ASND TTM cash flow from financing activities is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
ASND previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 2, 2025
ASND next earnings announcement is scheduled for May 2, 2025

OtherASNDcash flowmetrics:

TTM CFI

-
ASND TTM cash flow from investing activities value is unknown

TTM CFO

-
ASND TTM cash flow from operations value is unknown

TTM FCF

-
ASND TTM free cash flow value is unknown

TTM CAPEX

-
ASND TTM capital expenditures value is unknown

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

ASND Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+230.5%--
3 y3 years+15.6%--
5 y5 years-13.1%--

ASND Cash From Financing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+230.5%
5 y5-year-30.2%+230.5%
alltimeall time-30.2%>+9999.0%

Ascendis Pharma A/S Cash From Financing History

DateAnnualQuarterlyTTM
Dec 2024
$480.49 M(+230.5%)
-
-
Mar 2024
-
$20.01 M(-369.6%)
$166.15 M(+14.3%)
Dec 2023
$145.39 M(-65.3%)
-$7.42 M(-104.8%)
$145.39 M(-15.9%)
Sep 2023
-
$156.09 M(-6271.3%)
$172.90 M(-2923.4%)
Jun 2023
-
-$2.53 M(+235.5%)
-$6.12 M(-78.6%)
Mar 2023
-
-$754.00 K(-103.8%)
-$28.62 M(-106.8%)
Dec 2022
$418.44 M(+0.6%)
$20.09 M(-187.6%)
$418.43 M(+11.4%)
Sep 2022
-
-$22.94 M(-8.4%)
$375.47 M(-55.1%)
Jun 2022
-
-$25.03 M(-105.6%)
$835.33 M(-3.1%)
Mar 2022
-
$446.31 M(-2051.1%)
$862.04 M(+107.3%)
Dec 2021
$415.75 M(-39.6%)
-$22.87 M(-105.2%)
$415.75 M(-4.2%)
Sep 2021
-
$436.93 M(>+9900.0%)
$434.19 M(-36.3%)
Jun 2021
-
$1.68 M(+6856.0%)
$681.50 M(-1.2%)
Mar 2021
-
$24.10 K(-100.5%)
$689.50 M(+0.2%)
Dec 2020
$688.24 M(+24.6%)
-$4.44 M(-100.6%)
$688.24 M(-1.8%)
Sep 2020
-
$684.23 M(+6968.6%)
$701.16 M(+5019.4%)
Jun 2020
-
$9.68 M(-885.3%)
$13.70 M(+91.4%)
Mar 2020
-
-$1.23 M(-114.5%)
$7.16 M(-98.7%)
Dec 2019
$552.58 M(+130.2%)
$8.48 M(-362.4%)
$552.58 M(+0.7%)
Sep 2019
-
-$3.23 M(-202.9%)
$548.84 M(+0.1%)
Jun 2019
-
$3.14 M(-99.4%)
$548.22 M(+1.1%)
Mar 2019
-
$544.19 M(>+9900.0%)
$542.31 M(+125.9%)
DateAnnualQuarterlyTTM
Dec 2018
$240.02 M(+69.9%)
$4.74 M(-223.1%)
$240.02 M(-3.7%)
Sep 2018
-
-$3.85 M(+39.2%)
$249.21 M(-34.4%)
Jun 2018
-
-$2.77 M(-101.1%)
$379.67 M(-0.7%)
Mar 2018
-
$241.90 M(+1636.1%)
$382.46 M(+170.8%)
Dec 2017
$141.25 M(+8.6%)
$13.93 M(-89.0%)
$141.25 M(-45.0%)
Sep 2017
-
$126.61 M(>+9900.0%)
$256.60 M(+97.2%)
Jun 2017
-
$22.50 K(-96.7%)
$130.13 M(-0.4%)
Mar 2017
-
$686.00 K(-99.5%)
$130.69 M(+0.5%)
Dec 2016
$130.00 M(+10.8%)
$129.29 M(>+9900.0%)
$130.00 M(>+9900.0%)
Sep 2016
-
$137.00 K(-76.3%)
$541.60 K(-88.2%)
Jun 2016
-
$577.30 K(>+9900.0%)
$4.58 M(+57.5%)
Mar 2016
-
$0.00(-100.0%)
$2.91 M(-97.5%)
Dec 2015
$117.34 M(+84.2%)
-$172.70 K(-104.1%)
$117.34 M(-35.4%)
Sep 2015
-
$4.18 M(-481.5%)
$181.76 M(+2.7%)
Jun 2015
-
-$1.09 M(-101.0%)
$177.05 M(-0.6%)
Mar 2015
-
$114.43 M(+78.1%)
$178.14 M(+179.6%)
Dec 2014
$63.71 M(<-9900.0%)
$64.24 M(<-9900.0%)
$63.71 M(<-9900.0%)
Sep 2014
-
-$535.40 K(<-9900.0%)
-$535.40 K(<-9900.0%)
Jun 2014
-
$0.00(0.0%)
$0.00(0.0%)
Mar 2014
-
$0.00
$0.00
Dec 2013
-$292.20 K(+10.8%)
-
-
Dec 2012
-$263.60 K
-
-

FAQ

  • What is Ascendis Pharma A/S annual cash flow from financing activities?
  • What is the all time high annual CFF for Ascendis Pharma A/S?
  • What is Ascendis Pharma A/S annual CFF year-on-year change?
  • What is the all time high quarterly CFF for Ascendis Pharma A/S?
  • What is the all time high TTM CFF for Ascendis Pharma A/S?

What is Ascendis Pharma A/S annual cash flow from financing activities?

The current annual CFF of ASND is $480.49 M

What is the all time high annual CFF for Ascendis Pharma A/S?

Ascendis Pharma A/S all-time high annual cash flow from financing activities is $688.24 M

What is Ascendis Pharma A/S annual CFF year-on-year change?

Over the past year, ASND annual cash flow from financing activities has changed by +$335.10 M (+230.49%)

What is the all time high quarterly CFF for Ascendis Pharma A/S?

Ascendis Pharma A/S all-time high quarterly cash flow from financing activities is $684.23 M

What is the all time high TTM CFF for Ascendis Pharma A/S?

Ascendis Pharma A/S all-time high TTM cash flow from financing activities is $862.04 M